Off-Label Use

(Cancer Uses, Medically Acceptable Uses of Antineoplastics and Biologics)

The mission of AHFS Drug Information® (AHFS DI®) is to provide an evidence-based foundation for safe and effective drug therapy. Widely trusted for its established record in refuting unfounded efficacy claims, its rigorous science-based editorial process, and its independence from the influence of pharmaceutical manufacturers, AHFS DI has remained true to its mission for 50 years.

Supporting Documents

AHFS Off-label Uses Overview Editorial Independence of AHFS Drug Information AHFS Oncology Review Process for Oncology Off-label Uses AHFS Conflict of Interest and Disclosure Policy AHFS Oncology Expert Committee Members AHFS Levels of Evidence Rating System

Oncology Final Determinations

Azacitidine (use in AML with multilineage dysplasia; elderly AML patients intolerant of induction therapy) Bendamustine (use as first-line and salvage therapy for indolent non-Hodgkin's lymphoma and mantle cell lymphoma) Bortezomib (use as first-line therapy for previously untreated multiple myeloma) Cetuximab (use as first-line therapy in advanced-stage non-small cell lung cancer) Lenalidomide (use in transfusion-dependent, low-or intermediate-1 risk MDS without the deletion 5q abnormality) Levoleucovorin (use as first-line therapy for advanced-stage colorectal cancer) Zoledronic Acid (use in preventing aromatase inhibitor-induced bone loss)